The YCC internal and external advisory groups have provided invaluable guidance in planning and evaluation of all the major initiatives since the last NCI CCSG review, particularly during the last three years since the appointment of Dr. Lynch as Director. The Director has modified and improved the network of decision-making and advisory groups to include: ? The Director's Mini-Cabinet (Mini-Cab) is composed of the Director, Deputy Directors, and Associate Directors and meets weekly to evaluate progress in strategic YCC initiatives. ? The Executive Committee meets weekly to evaluate progress of all important initiatives and includes institutional and Research Program Leaders, plus the Mini-Cab members. ? The Internal Advisory Board, comprised of three senior leaders from the Yale School of Medicine, meets periodically with the Director to review pivotal YCC activities. ? The External Scientific Advisory Board (ESAB) has been expanded with the addition of several experienced Cancer Center leaders and includes 16 members, with complementary expertise in basic, translational, and population sciences. In addition, on the advice of the ESAB we have developed and are continually refining a Strategic Plan. With careful planning and evaluation by advisory groups, the YCC has successfully initiated the Strategic Plan, the reorganization of the Research Programs and their leadership, the integration of the new Smilow Cancer Hospital, and the substantial improvements in the clinical trials infrastructure. These coordinated teams of advisors provide critical advice and guidance, both annually in the fall and ad-hoc as required, ensuring that the YCC can most effectively set priorities and pursue objectives that help shape of basic, clinical, prevention and translational research at Yale.

Public Health Relevance

Program Planning and Evaluation is crucial to the effective functioning and long-term strategic planning of the YCC. Input and guidance from external and internal advisory groups has encouraged the growth of the Center during the project period and will continue to develop the YCC's strengths moving forward.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-35
Application #
8755647
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
35
Fiscal Year
2014
Total Cost
$34,789
Indirect Cost
$13,895
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Sarma, Elizabeth A; Kawachi, Ichiro; Poole, Elizabeth M et al. (2018) Social integration and survival after diagnosis of colorectal cancer. Cancer 124:833-840
Hartman, Douglas J; Ahmad, Fahad; Ferris, Robert L et al. (2018) Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma. Oral Oncol 86:278-287
Chen, Ling; Azuma, Takeshi; Yu, Weiwei et al. (2018) B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction. Proc Natl Acad Sci U S A 115:3126-3131
Zhang, Jinhua; Song, Kun; Wang, Jun et al. (2018) S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity. Oncoimmunology 7:e1296996
Kelada, Olivia J; Decker, Roy H; Nath, Sameer K et al. (2018) High Single Doses of Radiation May Induce Elevated Levels of Hypoxia in Early-Stage Non-Small Cell Lung Cancer Tumors. Int J Radiat Oncol Biol Phys 102:174-183
Powles, Ryan L; Redmond, David; Sotiriou, Christos et al. (2018) Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 4:e181564
Wang, Shi-Yi; Hsu, Sylvia H; Huang, Siwan et al. (2018) Regional Practice Patterns and Racial/Ethnic Differences in Intensity of End-of-Life Care. Health Serv Res 53:4291-4309
Gettinger, S N; Choi, J; Mani, N et al. (2018) A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nat Commun 9:3196
Liu, Huafeng; Li, Xin; Hu, Li et al. (2018) A crucial role of the PD-1H coinhibitory receptor in suppressing experimental asthma. Cell Mol Immunol 15:838-845
Altwerger, Gary; Bonazzoli, Elena; Bellone, Stefania et al. (2018) In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers. Mol Cancer Ther 17:1003-1011

Showing the most recent 10 out of 675 publications